While this study employed in vitro, ex vivo and in vivo models with breast and prostate cancer cells, the response to MSC CMs and the degree of inhibitory effects may depend on the types of cancer cells, hormonal receptor status and p53 mutations. The gene discussed is NR4A1; the disease is prostate cancer.